These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 16123729)

  • 1. Systemic overexpression of interleukin-10 fails to protect allogeneic islet transplants in nonobese diabetic mice.
    Zhang YC; Pileggi A; Molano RD; Wasserfall C; Campbell-Thompson M; Ricordi C; Atkinson MA; Inverardi L
    Transplantation; 2005 Aug; 80(4):530-3. PubMed ID: 16123729
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Interleukin-4 or interleukin-10 expressed from adenovirus-transduced syngeneic islet grafts fails to prevent beta cell destruction in diabetic NOD mice.
    Smith DK; Korbutt GS; Suarez-Pinzon WL; Kao D; Rajotte RV; Elliott JF
    Transplantation; 1997 Oct; 64(7):1040-9. PubMed ID: 9381527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adeno-associated virus-mediated IL-10 gene therapy inhibits diabetes recurrence in syngeneic islet cell transplantation of NOD mice.
    Zhang YC; Pileggi A; Agarwal A; Molano RD; Powers M; Brusko T; Wasserfall C; Goudy K; Zahr E; Poggioli R; Scott-Jorgensen M; Campbell-Thompson M; Crawford JM; Nick H; Flotte T; Ellis TM; Ricordi C; Inverardi L; Atkinson MA
    Diabetes; 2003 Mar; 52(3):708-16. PubMed ID: 12606512
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triptolide prolonged allogeneic islet graft survival in chemically induced and spontaneously diabetic mice without impairment of islet function.
    Xin MJ; Cui SH; Liu S; Sun HC; Li F; Sun JB; Luo B
    Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):312-8. PubMed ID: 20525560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early graft failure of xenogeneic islets in NOD mice is accompanied by high levels of interleukin-1 and low levels of transforming growth factor-beta mRNA in the grafts.
    Gysemans CA; Waer M; Valckx D; Laureys JM; Mihkalsky D; Bouillon R; Mathieu C
    Diabetes; 2000 Dec; 49(12):1992-7. PubMed ID: 11117999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with nondepleting anti-CD4 monoclonal antibodies but not CD28 antagonists protects islet graft in spontaneously diabetic nod mice from autoimmune destruction and allogeneic and xenogeneic graft rejection.
    Guo Z; Wu T; Kirchhof N; Mital D; Williams JW; Azuma M; Sutherland DE; Hering BJ
    Transplantation; 2001 Jun; 71(11):1656-65. PubMed ID: 11435979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recurrent autoimmunity accelerates destruction of minor and major histoincompatible islet grafts in nonobese diabetic (NOD) mice.
    Okitsu T; Bartlett ST; Hadley GA; Drachenberg CB; Farney AC
    Am J Transplant; 2001 Jul; 1(2):138-45. PubMed ID: 12099361
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunosuppression preventing concordant xenogeneic islet graft rejection is not sufficient to prevent recurrence of autoimmune diabetes in nonobese diabetic mice.
    Guo Z; Mital D; Shen J; Chong AS; Tian Y; Foster P; Sankary H; McChesney L; Jensik SC; Williams JW
    Transplantation; 1998 May; 65(10):1310-4. PubMed ID: 9625011
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BCG immunotherapy prevents recurrence of diabetes in islet grafts transplanted into spontaneously diabetic NOD mice.
    Lakey JR; Singh B; Warnock GL; Rajotte RV
    Transplantation; 1994 Apr; 57(8):1213-7. PubMed ID: 8178349
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deletion of STAT-1 pancreatic islets protects against streptozotocin-induced diabetes and early graft failure but not against late rejection.
    Callewaert HI; Gysemans CA; Ladrière L; D'Hertog W; Hagenbrock J; Overbergh L; Eizirik DL; Mathieu C
    Diabetes; 2007 Aug; 56(8):2169-73. PubMed ID: 17473223
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nondepleting anti-CD4 and soluble interleukin-1 receptor prevent autoimmune destruction of syngeneic islet grafts in diabetic NOD mice.
    Drage M; Zaccone P; Phillips JM; Nicoletti F; Dawson J; Andrew Bradley J; Cooke A
    Transplantation; 2002 Sep; 74(5):611-9. PubMed ID: 12352875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary nonfunction of islet grafts in autoimmune diabetic nonobese diabetic mice is prevented by treatment with interleukin-4 and interleukin-10.
    Faust A; Rothe H; Schade U; Lampeter E; Kolb H
    Transplantation; 1996 Sep; 62(5):648-52. PubMed ID: 8830831
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Islet allograft rejection in nonobese diabetic mice involves the common gamma-chain and CD28/CD154-dependent and -independent mechanisms.
    Demirci G; Strom TB; Li XC
    J Immunol; 2003 Oct; 171(7):3878-85. PubMed ID: 14500690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolonged islet graft survival in NOD mice by blockade of the CD40-CD154 pathway of T-cell costimulation.
    Molano RD; Berney T; Li H; Cattan P; Pileggi A; Vizzardelli C; Kenyon NS; Ricordi C; Burkly LC; Inverardi L
    Diabetes; 2001 Feb; 50(2):270-6. PubMed ID: 11272136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Depleting anti-CD4 monoclonal antibody cures new-onset diabetes, prevents recurrent autoimmune diabetes, and delays allograft rejection in nonobese diabetic mice.
    Makhlouf L; Grey ST; Dong V; Csizmadia E; Arvelo MB; Auchincloss H; Ferran C; Sayegh MH
    Transplantation; 2004 Apr; 77(7):990-7. PubMed ID: 15087759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination therapy with cyclosporine and interleukin-4 or interleukin-10 prolongs survival of synergeneic pancreatic islet grafts in nonobese diabetic mice: islet graft survival does not correlate with mRNA levels of type 1 or type 2 cytokines, or transforming growth factor-beta in the islet grafts.
    Rabinovitch A; Suarez-Pinzon WL; Sorensen O; Rajotte RV; Power RF
    Transplantation; 1997 Dec; 64(11):1525-31. PubMed ID: 9415551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene transfection and expression of transforming growth factor-beta1 in nonobese diabetic mouse islets protects beta-cells in syngeneic islet grafts from autoimmune destruction.
    Suarez-Pinzon WL; Marcoux Y; Ghahary A; Rabinovitch A
    Cell Transplant; 2002; 11(6):519-28. PubMed ID: 12428741
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Autoimmune destruction of islet grafts in the NOD mouse is resistant to 15-deoxyspergualin but sensitive to anti-CD4 antibody.
    Stegall MD; Loberman Z; Ostrowska A; Coulombe M; Gill RG
    J Surg Res; 1996 Aug; 64(2):156-60. PubMed ID: 8812627
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-TCR mAb induces peripheral tolerance to alloantigens and delays islet allograft rejection in autoimmune diabetic NOD mice.
    Deng R; Khattar M; Xie A; Schroder PM; He X; Chen W; Stepkowski SM
    Transplantation; 2014 Jun; 97(12):1216-24. PubMed ID: 24854475
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term islet graft survival in streptozotocin- and autoimmune-induced diabetes models by immunosuppressive and potential insulinotropic agent FTY720.
    Fu F; Hu S; Deleo J; Li S; Hopf C; Hoover J; Wang S; Brinkmann V; Lake P; Shi VC
    Transplantation; 2002 May; 73(9):1425-30. PubMed ID: 12023620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.